TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02830087

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet Cuff Pressure
Description: Tourniquet cuff pressure is how hard the tourniquet cuff, which is placed around the patient's thigh, presses on the thigh in order to cut off blood supply to the lower leg during total knee surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet Cuff Pressure
Description: Tourniquet cuff pressure is how hard the tourniquet cuff, which is placed around the patient's thigh, presses on the thigh in order to cut off blood supply to the lower leg during total knee surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet Cuff Pressure
Description: Tourniquet cuff pressure is how hard the tourniquet cuff, which is placed around the patient's thigh, presses on the thigh in order to cut off blood supply to the lower leg during total knee surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet Cuff Pressure
Description: Tourniquet cuff pressure is how hard the tourniquet cuff, which is placed around the patient's thigh, presses on the thigh in order to cut off blood supply to the lower leg during total knee surgery.
Study: NCT00850044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-450
Description: capsules,QD, one dose, see Arm Descriptions for more information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-450
Description: capsules,QD, one dose, see Arm Descriptions for more information
Study: NCT02830087

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet Cuff Pressure
Description: Tourniquet cuff pressure is how hard the tourniquet cuff, which is placed around the patient's thigh, presses on the thigh in order to cut off blood supply to the lower leg during total knee surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet Cuff Pressure
Description: Tourniquet cuff pressure is how hard the tourniquet cuff, which is placed around the patient's thigh, presses on the thigh in order to cut off blood supply to the lower leg during total knee surgery.
Study: NCT05675085

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Personalized screening protocol
Description: At the first screening round (recruitment) all participating women had the same tests;~* Two-view tomosynthesis of both breasts~* Calculation of volumetric breast density (VBD)~* Calculation of lifetime risk (LTR) using the Tyrer-Cuzick model~At subsequent rounds:~1. Women with non-dense breasts and low breast cancer risk are re-screened only with DBT every 2 years;~2. Women with dense breasts and low breast cancer risk are re-screened with DBT+US every 2 years;~3. Women with non-dense breasts and intermediate breast cancer risk are re-screened only with DBT every year;~4. Women with dense breasts and intermediate breast cancer risk are re-screened with DBT+US every year;~5. Women at high risk of breast cancer associated with a family history of breast cancer (w/wo hereditary factors) undergo DBT and MRI every year.
Study: NCT03927716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB206 12%
Description: Topically once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topically once daily
Study: NCT02633657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HORIZANT 300 mg
Description: HORIZANT 300 mg once daily
Study: NCT04002557

Intervention type: OTHER
Intervention: Interview-Questionnaire
Description: Questionnaire
Study: NCT00443326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 714
Description: Dosing Regimen is 6 Doses over 3 Months
Study: NCT02539693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine 75 µg/mL in sacrococcygeal block
Description: Sacrococcygeal block will be performed using 75 µg/mL clonidine in the anesthetic mixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine 150 µg/mL in sacrococcygeal block
Description: Sacrococcygeal block will be performed using 150 µg/mL clonidine in the anesthetic mixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 3 ml lidocaine 1% is injected at each block site

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 3 ml lidocaine 1% is injected at each block site

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pilonidal sinus
Description: Removal of pilonidal sinus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pilonidal sinus
Description: Removal of pilonidal sinus
Study: NCT02679092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 mcg buccal 60-90 minutes prior to procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400 mcg buccal 60-90 minutes prior to procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400 mcg buccal 60-90 minutes prior to procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 200 mg PO on the day prior to D\&E

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 200 mg PO on the day prior to D\&E

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hygroscopic cervical dilators
Description: osmotic cervical dilators inserted through the internal os

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hygroscopic cervical dilators
Description: osmotic cervical dilators inserted through the internal os
Study: NCT00290238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vertis Percutaneous Neuromodulation Therapy (PNT)
Description: * Ten PNT sessions in eleven weeks~* On average, one PNT session per week~* Ten lumbar Safeguide electrodes (three centimeters in length) deployed per lumbar montage~* Forty-five minutes of electrical stimulation for each session~* Electrical stimulation parameters:~  * Continuous 50 Hz current~ * Charge-balanced, biphasic (each phase is 200 microsec), rectangular waveform~ * Intensity to subject's tolerance for ten minutes then increased to a mildly uncomfortable level
Study: NCT03490864

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Melatonin (1mg) or placebo will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Melatonin (1mg) or placebo will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal Timing
Description: Subjects are instructed to maintain an extended overnight fasting period of 12-16 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal Timing
Description: Subjects are instructed to maintain an extended overnight fasting period of 12-16 hours.
Study: NCT00850044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: capsules, QD, one dose, escalating doses, see Arm Descriptions for more information
Study: NCT00290238

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: * Ten TENS sessions in eleven weeks~* On average, one TENS session per week~* Four 2-inch (5.1 centimeters) diameter pads applied per TENS lumbar montage~* Forty-five minutes of electrical stimulation for each session~* Electrical stimulation parameters:~  * Current at 2 Hz-low frequency~ * Pulse trains delivered as asymmetric, biphasic, square waveform current, with pulse width lasting 20 microsec~ * Intensity titrated according to subject's sensory threshold~ * To maintain blinding, the treating physician or clinician will check on the subject after 10 minutes and dial the channels down just prior to the point of turning off the device.
Study: NCT04419974

Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular Diagnosis
Description: Double-blind molecular diagnosis for the SCA3/MJD mutation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular Diagnosis
Description: Double-blind molecular diagnosis for the SCA3/MJD mutation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Scales - Baseline
Description: SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied on baseline.
Study: NCT03490864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NON Meal Timing
Description: Subjects are instructed to maintain their habitual meal timing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NON Meal Timing
Description: Subjects are instructed to maintain their habitual meal timing.
Study: NCT02053454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patisiran (ALN-TTR02)
Description: Ascending doses administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Calculated volume to match active comparator
Study: NCT04419974

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Scales - Baseline
Description: SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied on baseline.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Scales - Baseline
Description: SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied on baseline.
Study: NCT03016650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Patients receive 100 mL of physiologic saline with 1 g IV paracetamol 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Patients receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
Study: NCT03447353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanax 1Mg Tablet
Description: Single dose on two of four visits, one in conjunction with 1 tab of 10mg/325mg Norco

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanax 1Mg Tablet
Description: Single dose on two of four visits, one in conjunction with 1 tab of 10mg/325mg Norco
Study: NCT04419974

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw - Baseline
Description: Blood collection on baseline for evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw - Baseline
Description: Blood collection on baseline for evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw - Baseline
Description: Blood collection on baseline for evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins

Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of Life Assessment - Baseline
Description: Participants fill out 2 self-reported quality of life questionnaires.

Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of Life Assessment - Baseline
Description: Participants fill out 2 self-reported quality of life questionnaires.

Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of Life Assessment - Baseline
Description: Participants fill out 2 self-reported quality of life questionnaires.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Scales - Follow-up 12 months
Description: SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 12 months after baseline for prospective evaluation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Scales - Follow-up 12 months
Description: SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 12 months after baseline for prospective evaluation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Scales - Follow-up 12 months
Description: SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 12 months after baseline for prospective evaluation.
Study: NCT00850044

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for ABT-450
Description: capsules, QD, one dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for ABT-450
Description: capsules, QD, one dose
Study: NCT04419974

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw - Follow-up 12 months
Description: Blood collection 12 months after baseline for prospective evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw - Follow-up 12 months
Description: Blood collection 12 months after baseline for prospective evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins
Study: NCT00850044

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ritonavir
Description: capsules, QD, one dose
Study: NCT02208882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986120
Study: NCT04419974

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw - Follow-up 12 months
Description: Blood collection 12 months after baseline for prospective evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins

Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of Life Assessment - Follow-up 12 months
Description: Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.
Study: NCT02208882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04419974

Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of Life Assessment - Follow-up 12 months
Description: Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of Life Assessment - Follow-up 12 months
Description: Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Scales - Follow-up 24 months
Description: SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 24 months after baseline for prospective evaluation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Scales - Follow-up 24 months
Description: SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 24 months after baseline for prospective evaluation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Scales - Follow-up 24 months
Description: SARA, NESSCA, ICARS, INAS, SCAFI, CCFS will be applied 24 months after baseline for prospective evaluation.
Study: NCT06656455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol with oxygen via simple mask
Description: In group P, the sevoflurane will be discontinued, and propofol 1 mg/kg and fentanyl 1µg/kg will be administered IV. Propofol pump is maintained initially at a rate of 200mic/kg/min. with oxygen at 3 liters/min via facemask.~If movement requires interruption of the exam, a bolus of propofol 1mglkg is given and the infusion rate is increased by 20mic/kg/min up to a maximal rate of 350mic/kg/min. The total number of boluses needed will be recorded as the need for additional sedation. If apnea related to the depth of anesthesia occurs more than 10 sec or the saturation drops below 94%, the infusion pump will be stopped until the proper airway intervention is taken to achieve saturation above 95% with spontaneous breathing. Afterwards, the propofol pump will be resumed at a rate decreased by 20mic/kg/min.
Study: NCT04419974

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw - Follow-up 24 months
Description: Blood collection 24 months after baseline for prospective evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw - Follow-up 24 months
Description: Blood collection 24 months after baseline for prospective evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw - Follow-up 24 months
Description: Blood collection 24 months after baseline for prospective evaluation of~* Candidate genes expression~* Serum proteins~* Lymphocytic proteins

Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of Life Assessment - Follow-up 24 months
Description: Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of Life Assessment - Follow-up 24 months
Description: Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of Life Assessment - Follow-up 24 months
Description: Participants fill out 2 self-reported quality of life questionnaires for prospective evaluation.
Study: NCT03447353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norco 10Mg-325Mg Tablet
Description: Single dose on two of the four study visits, one in conjunction with 1mg alprazolam
Study: NCT04645056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching and Mobility exercises for neck and shoulder
Description: 9 specific stretching and mobility exercises performed 3 times every day the first 4 weeks after surgery.
Study: NCT01426646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.
Study: NCT03447353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norco 10Mg-325Mg Tablet
Description: Single dose on two of the four study visits, one in conjunction with 1mg alprazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Single dose on two of the four study visits, double dose on one of the four study visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Single dose on two of the four study visits, double dose on one of the four study visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Single dose on two of the four study visits, double dose on one of the four study visits
Study: NCT02465060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies
Study: NCT02208882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01426646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 plus cisplatin
Description: S-1 plus cisplatin every 3 weeks, a total of eight cycles~* S-1: 40mg/m2 orally twice daily (days 1-14)~* Cisplatin: 60mg/m2 IV on day 1
Study: NCT03842800

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: Patients and volunteers will receive an MRI.

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: Patients and volunteers will receive an MRI.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Patients and volunteers will receive an MRI.

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: Patients and volunteers will receive an MRI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be administered to a subset of healthy controls that agree to receive the drug as part of receiving an MRI.
Study: NCT02851524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: posturography
Study: NCT02465060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies
Study: NCT02208882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam